1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Valeant Keeps full year earnings guidance unchanged

Discussion in 'Valeant Pharmaceuticals' started by RobertPhillips900, Nov 7, 2017 at 9:49 AM.

  1. RobertPhillips900

    Joined:
    Aug 29, 2016
    Messages:
    51
    Likes Received:
    0
    Valeant posted a quarterly profit helped by the strong performance of its Bausch and Lomb Business.
    Net income attributable to Valeant rose to $1.30Bil, or $3.69 per share, during the quarter , compared with a loss of $1.22Bil, or $3.49 per share, a year earlier.

    Total revenue fell 10.5% to $2.22Bil, reflecting volume declines in its US diversified products and branded businesses.

    Take a look at the earnings highlights including the guidance http://alph.st/b07a566e
     

  2. anonymous

    anonymous Guest

    Nice try. Still a garbage company that no one wants to work for.